| . | Apatinib Dosing Protocol . | P Value . | |
|---|---|---|---|
| 750 mg (n = 10) . | 500 mg (n = 10) . | ||
| Age, y, mean ± SD (range) | 55.3 ± 14.42 (33–78) | 54.0 ± 13.64 (27–70) | 0.84 |
| Sex, male/female | 5/5 | 5/5 | 0.67 |
| Pathology | 0.37 | ||
| PTC | 9 | 6 | |
| FTC | 0 | 2 | |
| PoorlyPTC | 1 | 2 | |
| Median RAI accumulation, mCi (range) | 315 (200–630) | 410 (150–1150) | 0.12 |
| VEGF mutation | 1.00 | ||
| Positive | 4 | 3 | |
| Negative | 5 | 6 | |
| NA | 1 | 1 | |
| Therapy before apatinib | 1.00 | ||
| Surgery, RIT | 8 | 7 | |
| Surgery, RIT, sorafenib | 2 | 2 | |
| Surgery, RIT, sorafenib, vandetanib | 0 | 1 | |
| ECOG performance status | 0.65 | ||
| 0 | 3 | 4 | |
| 1 | 7 | 5 | |
| 2 | 0 | 1 | |
| . | Apatinib Dosing Protocol . | P Value . | |
|---|---|---|---|
| 750 mg (n = 10) . | 500 mg (n = 10) . | ||
| Age, y, mean ± SD (range) | 55.3 ± 14.42 (33–78) | 54.0 ± 13.64 (27–70) | 0.84 |
| Sex, male/female | 5/5 | 5/5 | 0.67 |
| Pathology | 0.37 | ||
| PTC | 9 | 6 | |
| FTC | 0 | 2 | |
| PoorlyPTC | 1 | 2 | |
| Median RAI accumulation, mCi (range) | 315 (200–630) | 410 (150–1150) | 0.12 |
| VEGF mutation | 1.00 | ||
| Positive | 4 | 3 | |
| Negative | 5 | 6 | |
| NA | 1 | 1 | |
| Therapy before apatinib | 1.00 | ||
| Surgery, RIT | 8 | 7 | |
| Surgery, RIT, sorafenib | 2 | 2 | |
| Surgery, RIT, sorafenib, vandetanib | 0 | 1 | |
| ECOG performance status | 0.65 | ||
| 0 | 3 | 4 | |
| 1 | 7 | 5 | |
| 2 | 0 | 1 | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FTC, follicular thyroid cancer; NA, not available; PTC, papillary thyroid cancer; Poorly-PTC, poorly differentiated thyroid cancer; RIT, radioactive iodine therapy; VEGF, vascular endothelial growth factor.
| . | Apatinib Dosing Protocol . | P Value . | |
|---|---|---|---|
| 750 mg (n = 10) . | 500 mg (n = 10) . | ||
| Age, y, mean ± SD (range) | 55.3 ± 14.42 (33–78) | 54.0 ± 13.64 (27–70) | 0.84 |
| Sex, male/female | 5/5 | 5/5 | 0.67 |
| Pathology | 0.37 | ||
| PTC | 9 | 6 | |
| FTC | 0 | 2 | |
| PoorlyPTC | 1 | 2 | |
| Median RAI accumulation, mCi (range) | 315 (200–630) | 410 (150–1150) | 0.12 |
| VEGF mutation | 1.00 | ||
| Positive | 4 | 3 | |
| Negative | 5 | 6 | |
| NA | 1 | 1 | |
| Therapy before apatinib | 1.00 | ||
| Surgery, RIT | 8 | 7 | |
| Surgery, RIT, sorafenib | 2 | 2 | |
| Surgery, RIT, sorafenib, vandetanib | 0 | 1 | |
| ECOG performance status | 0.65 | ||
| 0 | 3 | 4 | |
| 1 | 7 | 5 | |
| 2 | 0 | 1 | |
| . | Apatinib Dosing Protocol . | P Value . | |
|---|---|---|---|
| 750 mg (n = 10) . | 500 mg (n = 10) . | ||
| Age, y, mean ± SD (range) | 55.3 ± 14.42 (33–78) | 54.0 ± 13.64 (27–70) | 0.84 |
| Sex, male/female | 5/5 | 5/5 | 0.67 |
| Pathology | 0.37 | ||
| PTC | 9 | 6 | |
| FTC | 0 | 2 | |
| PoorlyPTC | 1 | 2 | |
| Median RAI accumulation, mCi (range) | 315 (200–630) | 410 (150–1150) | 0.12 |
| VEGF mutation | 1.00 | ||
| Positive | 4 | 3 | |
| Negative | 5 | 6 | |
| NA | 1 | 1 | |
| Therapy before apatinib | 1.00 | ||
| Surgery, RIT | 8 | 7 | |
| Surgery, RIT, sorafenib | 2 | 2 | |
| Surgery, RIT, sorafenib, vandetanib | 0 | 1 | |
| ECOG performance status | 0.65 | ||
| 0 | 3 | 4 | |
| 1 | 7 | 5 | |
| 2 | 0 | 1 | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FTC, follicular thyroid cancer; NA, not available; PTC, papillary thyroid cancer; Poorly-PTC, poorly differentiated thyroid cancer; RIT, radioactive iodine therapy; VEGF, vascular endothelial growth factor.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
